A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.
Humans
Middle Aged
COVID-19 Vaccines
/ immunology
Adult
Antibodies, Neutralizing
/ blood
Aged
Male
Female
Immunization, Secondary
/ methods
Young Adult
Antibodies, Viral
/ blood
Adolescent
Aged, 80 and over
COVID-19
/ prevention & control
SARS-CoV-2
/ immunology
Orf virus
/ immunology
Immunogenicity, Vaccine
Spike Glycoprotein, Coronavirus
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Genetic Vectors
COVID-19
ORF virus-vector
SARS-CoV-2 variants
booster vaccine
first-in-human trial
immunogenicity
safety
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
31 Dec 2024
31 Dec 2024
Historique:
medline:
14
10
2024
pubmed:
14
10
2024
entrez:
14
10
2024
Statut:
ppublish
Résumé
Next-generation COVID-19 vaccines are being developed to expand the breadth of coverage against existing and future variants and to extend the duration of protection. Prime-2-CoV_Beta is an orf virus (ORFV) based multi-antigen COVID-19 vaccine that co-expresses Spike (S) and Nucleocapsid (N) antigens. The safety and immunogenicity of Prime-2-CoV_Beta is investigated in a phase 1 first-in-human (FIH) dose-finding trial (ORFEUS study, ClinicalTrials.gov: NCT05367843). Participants of two age groups (18-55 and 65-85 years) who previously completed at least two doses of mRNA vaccines were enrolled and sequentially assigned to different dose groups to receive one intramuscular dose of 3 × 10
Identifiants
pubmed: 39397784
doi: 10.1080/21645515.2024.2410574
doi:
Substances chimiques
COVID-19 Vaccines
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
Banques de données
ClinicalTrials.gov
['NCT05367843']
Types de publication
Journal Article
Clinical Trial, Phase I
Langues
eng
Sous-ensembles de citation
IM